A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
Public ClinicalTrials.gov record NCT01304784. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 and Pharmacologic Study of MM-111 in Combination With Multiple Treatment Regimens in Patients With Advanced HER2 Positive Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
Study identification
- NCT ID
- NCT01304784
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2011 (Type not available)
- Primary completion
- Apr 2014 (Actual)
- Completion
- Jun 2014 (Actual)
- Last update posted
- Dec 16, 2015
2011 – 2014
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Georgia Cancer Specialists | Atlanta | Georgia | 30342 | — |
| Central Indiana Cancer Centers | Indianapolis | Indiana | 46151 | — |
| Horizon Oncology Research, Inc | Lafayette | Indiana | 47908 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89135 | — |
| New York Oncology/Hematology | Albany | New York | 12206 | — |
| Innovation Center - Kettering Medical Center Health Network | Kettering | Ohio | 45429 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| GHS Institute of Transitional Oncology Research | Greenville | South Carolina | 29605 | — |
| Texas Oncology Cancer Center | Austin | Texas | 78731 | — |
| Texas Oncology PA North/Sammans Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Evergreen Hematology and Oncology | Spokane | Washington | 99218 | — |
| Northwest Cancer Specialists-Vancouver Cancer Center | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01304784, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2015 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01304784 live on ClinicalTrials.gov.